Endothelin receptor antagonists in a beagle model of pulmonary hypertension: contribution to possible potential therapy?
M Okada,
C Yamashita,
M Okada,
and
K Okada
Department of Surgery, Kobe University School of Medicine, Japan.
OBJECTIVES. This study investigated the pharmacologic effect of endothelin receptor antagonists on cardiopulmonary hemodynamic variables in a beagle model of pulmonary hypertension. BACKGROUND. We recently developed a beagle model of pulmonary hypertension that allows accurate determination of cardiopulmonary hemodynamic variables and is associated with elevated plasma endothelin-1 concentrations similar to those in pulmonary hypertension in humans. METHODS. Twelve beagles (pulmonary hypertension, n = 6; control group, n = 6) were studied during baseline conditions and during right atrial infusion of FR139317 (an ETA receptor antagonist), RES-701-1 (an ETB receptor antagonist), nitroglycerin and prostaglandin E1. Pulmonary hypertension was induced in experimental beagles 8 weeks after injection with 3 mg/kg body weight of dehydromonocrotaline. RESULTS. FR139317 lowered pulmonary artery and systemic arterial pressures in both pulmonary hypertensive and control beagles, with a significantly greater effect on pulmonary artery pressure in pulmonary hypertensive dogs. RES-701-1 tended to increase pulmonary artery pressure only in pulmonary hypertensive beagles. Nitroglycerin depressed pulmonary artery and systemic arterial tone equally well in control and pulmonary hypertensive animals. Prostaglandin E1 produced a greater decrease in systemic arterial pressure in pulmonary hypertensive than in normal beagles despite having the same effect on pulmonary artery pressure in both. CONCLUSIONS. ETA receptor antagonists decrease pulmonary artery pressure in a beagle model and may therefore be clinically useful for treatment of pulmonary hypertension.
This article has been cited by other articles:
|
|
|
|
 
W. Johnson, A. Nohria, L. Garrett, J. C. Fang, J. Igo, M. Katai, P. Ganz, and M. A. Creager
Contribution of endothelin to pulmonary vascular tone under normoxic and hypoxic conditions
Am J Physiol Heart Circ Physiol,
August 1, 2002;
283(2):
H568 - H575.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. A Markewitz, I. S Farrukh, Y. Chen, Y. Li, and J. R Michael
Regulation of endothelin-1 synthesis in human pulmonary arterial smooth muscle cells: effects of transforming growth factor-{beta} and hypoxia
Cardiovasc Res,
January 1, 2001;
49(1):
200 - 206.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Schmeck, H. Gluth, N. Mihaljevic, M. Born, M. Wendel-Wellner, and P. Krafft
ET-1-induced pulmonary vasoconstriction shifts from ETA- to ETB-receptor-mediated reaction after preconstriction
J Appl Physiol,
December 1, 1999;
87(6):
2284 - 2289.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Dupuis and S. Prie
The ETA-Receptor Antagonist LU 135252 Prevents the Progression of Established Pulmonary Hypertension Induced by Monocrotaline in Rats
Journal of Cardiovascular Pharmacology and Therapeutics,
January 1, 1999;
4(1):
33 - 39.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. Dupuis, G. W Moe, and P. Cernacek
Reduced pulmonary metabolism of endothelin-1 in canine tachycardia-induced heart failure
Cardiovasc Res,
September 1, 1998;
39(3):
609 - 616.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Prie, D. J. Stewart, and J. Dupuis
EndothelinA Receptor Blockade Improves Nitric Oxide Mediated Vasodilation in Monocrotaline-Induced Pulmonary Hypertension
Circulation,
June 2, 1998;
97(21):
2169 - 2174.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. N. Willette, E. H. Ohlstein, M. P. Mitchell, C. F. Sauermelch, G. R. Beck, M. A. Luttmann, and D. W. P. Hay
Nonpeptide Endothelin Receptor Antagonists. VIII: Attenuation of Acute Hypoxia-Induced Pulmonary Hypertension in the Dog
J. Pharmacol. Exp. Ther.,
February 1, 1997;
280(2):
695 - 701.
[Abstract]
[Full Text]
|
|
|
|
